Eldelumab and Fenofibrate show potential for COVID-19

790251

Sumary of Eldelumab and Fenofibrate show potential for COVID-19:

  • Based on computational analysis, researchers have discovered multiple drugs that target specific genes and pathways altered in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and had the potential to be potential treatments..
  • Although the COVID-19 has been raging around the globe for more than a year, there are have been few drugs found that are effective against the disease..
  • Repurposing drugs already approved to treat other diseases can significantly cut down the time to develop new treatments for the disease..
  • Analyzing differentially expressed genes from RNA-Seq can help us better understand the infection process and find drugs that can be repurposed..
  • In a new study posted to the medRxiv* preprint server, researchers from the University of Pittsburgh and Barrow Neurological Institute report the results of their analysis of several RNA-Seq studies and used computational approaches to discover potential drugs against COVID-19..
  • Computational analysis Researchers searched the CLC Genomics Workbench database for RNA-Seq data for SARS-CoV-2..
  • They next obtained drug information and mechanism of action from a commercial drug database and when used in combination with all the known genes involved in COVID-19, to come up with a list of possible drug candidates..
  • Their analysis revealed 283 differentially expressed genes and pathway analysis identified 27 diseases and disorders, 21 cellular and molecular functions, and 275 general pathways….

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close